{"filing":{"accession_number":"0001213900-26-086190","cik":"0001553643","ticker":"RLMD","company_name":"RELMADA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ea0300993-8k_relmada.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/ea0300993-8k_relmada.htm"},"events":[{"id":24619,"run_id":22319,"accession_number":"0001213900-26-086190","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Relmada Therapeutics reported Q2 2026 financial results, including a net loss of $12.9 million, R\u0026D expenses of $8.4 million, and cash balance of $217.7 million, along with a business update on pipeline programs (NDV-01, sepranolone) and corporate developments.","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25237,"accession_number":"0001213900-26-086190","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Relmada's financial results for Q2 2026 (three and six months ended June 30, 2026), including condensed consolidated balance sheets, statements of operations, and stockholders' equity. The press release reports net loss of $12.9 million for Q2 2026, R\u0026D expenses of $8.4 million, cash balance of $217.7 million, and loss per share of $0.11. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:23:12.792729+00:00","company_name":"","ticker":null,"filing_date":""},{"id":25238,"accession_number":"0001213900-26-086190","item_number":"7.01","item_title":"Regulation","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1) contain a press release dated August 6, 2026, titled \"Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update.\" The press release explicitly reports Q2 2026 financial results (R\u0026D expense, G\u0026A expense, net loss, cash balance, EPS) alongside business updates on pipeline programs (NDV-01, sepranolone) and corporate developments (CBO appointment). This is a standard earnings release disclosure for a clinical-stage biotech company, material to investors assessing the company's financial position and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:23:12.792729+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25237,"accession_number":"0001213900-26-086190","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Relmada's financial results for Q2 2026 (three and six months ended June 30, 2026), including condensed consolidated balance sheets, statements of operations, and stockholders' equity. The press release reports net loss of $12.9 million for Q2 2026, R\u0026D expenses of $8.4 million, cash balance of $217.7 million, and loss per share of $0.11. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:23:12.792729+00:00","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-08-06"},{"id":25238,"accession_number":"0001213900-26-086190","item_number":"7.01","item_title":"Regulation","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1) contain a press release dated August 6, 2026, titled \"Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update.\" The press release explicitly reports Q2 2026 financial results (R\u0026D expense, G\u0026A expense, net loss, cash balance, EPS) alongside business updates on pipeline programs (NDV-01, sepranolone) and corporate developments (CBO appointment). This is a standard earnings release disclosure for a clinical-stage biotech company, material to investors assessing the company's financial position and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:23:12.792729+00:00","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-08-06"}]}